DRUG · COUNSELLING NOTES
Omalizumab
XOLAIR
Updated
New prescription
indication: _____. SC q2-4wk, observed after dose; carry epinephrine if prescribed; warned on allergies; serious/common AEs: anaphylaxis, injection reaction, headache; non-pharm: trigger avoidance.
Refill prescription
refilled, adherence discussed, no SEs were reported
Dose change
Dose change discussed. new dose reviewed; SC q2-4wk, observed after dose; carry epinephrine if prescribed; warned on allergies; serious/common AEs: anaphylaxis, injection reaction, headache; non-pharm: trigger avoidance.